Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avicena’s Parkinson’s trial generates positive results
Data demonstrated that neither PD-02 nor minocycline was found to be futile as compared to predetermined thresholds, suggesting both agents may be worthy of further consideration as potential
Data demonstrated that neither PD-02 nor minocycline was found to be futile as compared to predetermined thresholds, suggesting both agents may be worthy of further consideration as potential
For this study, VirtualScopics will analyze magnetic resonance imaging (MRI) data on subjects with osteoarthritis, and will be responsible for co-managing the collection of MRI data from sites
The studies assessed the safety and tolerability of AZD6140 plus aspirin compared with Plavix plus aspirin in patients with non-ST elevation acute coronary syndromes. These data were presented
Under the terms of the agreement, ActivX will apply its novel chemical technologies and high-throughput protein analysis to a number of Pfizer programs spanning drug discovery, polemic profiling,
In the study, patients treated with AzaSite had a significantly higher clinical resolution rate, the trial’s primary efficacy end point, and a significantly higher bacterial eradication rate, a
The phase I trial will be an open-label, dose-escalation clinical trial of IT-101 in patients with all types of cancer. The trial is expected to enroll between 24
According to the company, erythropoietin (EPO) has a worldwide market exceeding $11 billion and is growing at an average annual rate of 18% for the past five years.
The company wanted to access the safety and tolerability of the drug, NXY-059, in intracerebral hemorrhage (ICH) as treatment may be initiated before a scan has confirmed diagnosis
Amgen, the world’s largest biotechnology company, said that treating anemia with Aranesp in patients with symptomatic heart failure was well-tolerated, effectively raised hemoglobin levels and improved patients’ symptoms.
The patents cover the use of GLP-1 analogues alone or in combination with insulins for the treatment of type I diabetes. Under the terms of the Agreement, Transition